Publication

Accounting for EGFR Mutations in Epidemiologic Analyses of Non-Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data.

Journal Paper/Review - Mar 1, 2022

Units
PubMed
Doi
Contact

Citation
Schmid S, Jiang M, Brown M, Fares A, Garcia M, Soriano J, Dong M, Thomas S, Kohno T, Leal L, Diao N, Xie J, Wang Z, Zaridze D, Holcatova I, Lissowska J, Świątkowska B, Mates D, Savic M, Wenzlaff A, Harris C, Caporaso N, Ma H, Fernandez-Tardon G, Barnett M, Goodman G, Davies M, Pérez-Ríos M, Taylor F, Duell E, Schoettker B, Brenner H, Andrew A, Cox A, Ruano-Ravina A, Field J, Marchand L, Wang Y, Chen C, Tardon A, Shete S, Schabath M, Shen H, Landi M, Ryan B, Schwartz A, Qi L, Sakoda L, Brennan P, Yang P, Zhang J, Christiani D, Reis R, Shiraishi K, Hung R, Xu W, Liu G. Accounting for EGFR Mutations in Epidemiologic Analyses of Non-Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data. Cancer Epidemiol Biomarkers Prev 2022; 31:679-687.
Type
Journal Paper/Review (English)
Journal
Cancer Epidemiol Biomarkers Prev 2022; 31
Publication Date
Mar 1, 2022
Issn Electronic
1538-7755
Pages
679-687
Brief description/objective

Somatic EGFR mutations define a subset of non-small cell lung cancers (NSCLC) that have clinical impact on NSCLC risk and outcome. However, EGFR-mutation-status is often missing in epidemiologic datasets. We developed and tested pragmatic approaches to account for EGFR-mutation-status based on variables commonly included in epidemiologic datasets and evaluated the clinical utility of these approaches.